Product Information
KALETRA 200-50 MG TABLET is a brand product labeled by AbbVie Inc., priced at $8.3041 per EA under NDC 00074401412. Its NADAC has been published 45 times since Jul 10, 2024.
Strength
200; 50 mg/1; mg/1
Manufacturer
AbbVie Inc.NDC
00074401412
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
7/10/2024
Active Ingredients
LOPINAVIR; RITONAVIRApproval Type
New Drug (NDA)
FDA Application
NDA021906On Market Since
4/8/2020
Pharmacological Classes
Price Statistics
The NADAC for KALETRA 200-50 MG TABLET has been published 45 times since Jul 10, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.3041 per EA |
|---|---|
| All-time high | $8.3041 (May 14, 2025) |
| All-time low | $8.3041 (Jul 10, 2024) |
| Median price | $8.3041 |
| Average price | $8.3041 |
| Largest weekly change | 0.0% (Jul 17, 2024) |
| Weeks tracked | 45 |
| Tracking since | Jul 10, 2024 |
Generic Alternatives
The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 47% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of KALETRA 200-50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for KALETRA 200-50 MG TABLET, manufactured by AbbVie Inc., is $8.3041 per EA (NDC 00074401412), effective May 14, 2025.
How has the price of KALETRA 200-50 MG TABLET changed over time?
Over the history we have for it, the NADAC for KALETRA 200-50 MG TABLET has held within roughly two percent of its current level. It has been tracked across 45 weekly CMS publications since Jul 10, 2024.
What are the highest and lowest recorded NADAC prices for KALETRA 200-50 MG TABLET?
Since Jul 10, 2024, the NADAC for KALETRA 200-50 MG TABLET has ranged from a low of $8.3041 (Jul 10, 2024) to a high of $8.3041 (May 14, 2025), with a median of $8.3041 per EA.
Are there cheaper alternatives to KALETRA 200-50 MG TABLET?
Yes. 2 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, LOPINAVIR-RITONAVR 200-50 MG TB, is $4.4210 per EA — about 47% below KALETRA 200-50 MG TABLET.
Who manufactures KALETRA 200-50 MG TABLET?
KALETRA 200-50 MG TABLET (NDC 00074401412) is labeled by AbbVie Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification